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High molecular weight protein toxins produced by bacteria, e.g. staphylococcal 
enterotoxins and botulinum neurotoxins, as well as plant toxins such as ricin and 
abrin, are relevant analytes in different application areas: food safety, public 
health, civil security and defense sector, and – in case of botulinum neurotoxins – 
also in pharmaceutics. For their reliable and accurate detection, identification and 
quantification, reference materials (RMs), in particular certified reference 
material (CRM), are required. The present article focuses on challenges in the 
development (production and certification) of such RMs. Firstly, it highlights the 
role of RMs and CRMs, what they can be used for, the nature of certified 
properties, metrological traceability, and uncertainty of certified values, as well 
as commutability of RMs. Secondly, the molecule-specific technical challenges 
are highlighted using the example of the mentioned toxins. This includes for 
instance the choice of a suitable purification strategy (recombinant expression and 
purification versus the purification of toxin from natural sources), the in-depth 
characterization of the obtained preparations by a comprehensive set of methods 
including immunochemical assays, mass spectrometry, and functional assays to 
verify their identity and establish their purity and activity, and finally, suitable 
approaches for determining reference values of important toxin properties (protein 
mass concentration in solution, biological activity). The article summarizes 
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ongoing activities in a new European initiative called EuroBioTox, which aims at 
the production and certification of RMs for selected protein toxins and the 
establishment of validated procedures for the detection and identification of 
biological toxins.  
 
Biological Toxins  
Biological toxins are a large group of hazardous substances produced by living 
organisms such as bacteria, plants, or animals, which exert a detrimental effect on 
other organisms upon uptake. Among those, high molecular weight protein toxins 
deserve special attention since they are relevant in different fields: Bacterial toxins 
such as staphylococcal enterotoxins (SE) or botulinum neurotoxins (BoNT) are 
known as causative agents of food poisoning outbreaks and are therefore 
monitored by national and international food and health agencies 1-3. On the other 
hand, the same toxins have been linked to military research programs in the past 
where staphylococcal enterotoxin B (SEB) has been explored as incapacitating 
agent and BoNT has been weaponized under the code name “X” 4-6. Along the 
same line, the plant toxins ricin or abrin have long been known to induce natural 
intoxications in humans and animals 7-8. Ricin, similar to BoNT, has a history of 
military research (code name “W”) and is the only protein toxin listed in Schedule 
1 of the Chemical Weapons Convention9. Based on the potential threat level in 
public health incidents, BoNT as well as ricin and SE have been classified as 
bioterrorism agents of the highest (BoNT) or second highest (ricin, SE) category 
10-11. 
 
Recent incidents in Europe and worldwide have threatened civil society by the 
attempted use of different biological toxins. Exemplarily, in June 2018 a 
biological terror attack was thwarted in Cologne, Germany, where the suspect was 
accused of having manufactured ricin and acquired bomb-making materials for a 
serious act of violence against the state 12. Therefore, increased vigilance and 
adequate preparation is of importance in a world facing growing risks of man-
made disasters.  
 
From an analytical perspective, protein toxins have several commonalities even 
though they are produced by different organisms and have quite different 
structures and functions 13:  
1) They are toxic in the absence of the producing organism and its genetic 
information. Therefore, detection has to focus on protein-based methods, 
DNA-based methods are not sufficient in most instances. 
2) Their very high toxicity demands for highly sensitive methods, optimally with 
detection limits in the pg/mL range when different sample types are analyzed. 
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3) They are rapidly metabolized after uptake in the human body, limiting the time 
window for detection in clinical specimens. 
4)  Finally and most challenging, they are often produced in multiple variants or 
isoforms which might differ in their toxicokinetics and toxicodynamics. 
 
Detailed information on the individual toxins, their biological structure and 
function has been reviewed elsewhere (for an overview please see 13-16). Briefly, 
for the detection of biological toxins, a variety of methods has been established 
based on immunological, spectrometric, and functional assays or combinations 
thereof – all of those have advantages and limitations. Among those, 
immunoassays such as sandwich enzyme-linked immunosorbent assays (ELISA) 
display the presence of the analyte and highlight the native folding of the molecule 
depending on the antibodies used 13, 17-19. Among all technologies available, 
ELISA-based methods still provide the highest sensitivity with detection limits in 
the ng/mL to fg/mL range provided that high-affinity antibodies are used 18-19. 
However, for ELISA-based methods, the recognition of individual toxin variants 
has to be comprehensively tested, and the discrimination of closely related toxin 
variants is not always feasible 20-22. In this context, mass spectrometry methods 
(e.g., matrix-assisted laser desorption ionization—time of flight mass 
spectrometry (MALDI-TOF-MS) and liquid chromatography-electrospray 
ionization-tandem mass spectrometry (LC-ESI MS)) are able to deliver 
unambiguous sequence information and therefore provide reliable identification 
of toxins. With modern instrumentation, sensitivities are still somewhat limited 
and can reach down to a few ng/mL of toxin, especially when combinations of 
immunoaffinity-based enrichment, tryptic digestion plus MS-based detection and 
identification of specific peptides is applied 18-19, 23-24. Finally, functional methods 
display the biological activity or potency of protein toxins. Here, many different 
approaches have been described for the individual toxins ranging from in vivo 
assays (e.g., mouse bioassay for BoNT), ex vivo assays using animal tissues (e.g., 
mouse phrenic nerve hemidiaphragm assay for BoNT) or in vitro assays which 
renounce te use of animal tissues 25-27. Depending on the protein toxin, functional 
in vitro assays display receptor binding, internalization and enzymatic activity or 
only parts thereof (e.g., cytotoxicity assay versus adenine release assay for ricin 
and abrin; endopeptidase assay for BoNT 28-30) or they display the interaction of 
toxins with their physiological targets (e.g., TCR / MHC-binding in a mixed 
lymphocyte reaction for SE 31).  
 
In the past, an objective comparison of the different methods has not been possible 
since no suitable RM and no opportunity for proficiency testing has been 
available. In light of the relevance of biological toxins in the food, health and 
security sectors and in order to establish the status quo of detection capabilities 
within the European Union (EU) and beyond, a project called EQuATox was 
funded by the EU’s 7th framework program from 2012 to 2014 (EQuATox, 
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“Establishment of Quality Assurances for the Detection of Biological Toxins of 
Potential Bioterrorism Risk”) 1, 32-33. Here, the evaluation of technical capabilities 
in a series of proficiency tests (PTs) showed that mostly satisfactory results were 
obtained in international expert laboratories when dealing with basic analytical 
tasks; still the equivalence of analytical results would clearly profit from further 
technical improvement 1, 13, 18-19, 34. Among other findings, it became clear that 
expert laboratories use indeed a broad panel of different tools and technical 
approaches for detection, identification and quantification of biological toxins 
resulting in data of variable quality. Though validation studies were published for 
individual methods, there are currently hardly any agreed-upon reference methods 
available, nor are there RMs available for the toxins in focus (ricin, abrin, SE, 
BoNT). So expert laboratories currently use either own in-house purified 
materials or commercial toxins of varying quality as quality-control (QC) samples 
or for calibration, which makes any comparison of different methods applied in 
different laboratories questionable 13.  
 
As an outcome of the project, a roadmap for harmonization of detection methods 
for biological toxins was drafted 13 which is now implemented in the ongoing 
EuroBioTox project funded by the EU’s Horizon 2020 program from 2017 to 
2022 (“European Programme for the Establishment of Validated Procedures for 
the Detection and Identification of Biological Toxins”) 35-36. In this project, 13 
core members join their forces together with 48 network partners from 23 
countries to work on a comprehensive package of quality assurance measures, 
including the production and certified reference materials (CRMs), the refinement 
of analytical procedures, the availability of tools in a European repository, state-
of-the-art training on good analytical strategies, and the establishment of a 
comprehensive proficiency testing scheme. A major focus of the project is the 
production of CRMs for prioritized biological toxins such as ricin, BoNT and 
SEB. 
 
On the Importance of Quality-Control Tools 
In case of a natural (i.e., food poisoning outbreak) or intentional release (i.e., 
bioterrorism threat scenario) of biological toxins, decision makers rely on correct 
and reliable laboratory data to make appropriate and timely decisions, to manage 
the threat and to alleviate the outcomes on society. In this context, a high level of 
analytical capability is required to understand the scale of the incident and to take 
qualified decisions on countermeasures 13. Generally, several components are 
needed in order to perform reliable measurements: 
 Good analytical strategies 
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 Validated methods for screening, identification, quantification and 
measurement of biological activity; the latter allows for the 
determination of the biological threat level 
 RMs, preferably certified RMs (ideally both pure toxin solutions 
(“calibrants”) as well as toxin in matrix materials) 
 Standard operating procedures 
 Regular training of personnel 
 External evaluation of measurement capabilities by proficiency testing 
 Continuous refinement of methods and development of 
innovative/superior methods 
The use of QC tools properly characterized with respect to identity and purity is 
an important requirement to achieve accurate and reliable results in the 
measurement of biological toxins 37. By definition, ISO Guide 30 defines an RM 
as a material which is sufficiently homogeneous and stable with respect to one or 
more specified properties, which has been established to be fit for its intended use 
in a measurement process 38. The property is the entity for which a reference value 
is established. This property can be qualitative (e.g., identity of species: genomic 
DNA of Listeria monocytogenes, strain 4B, NCTC 11994), but in most cases it is 
quantitative (e.g., mass concentration of a given protein in a matrix: amyloid β1-
42 peptide in human cerebrospinal fluid, 0.72 ± 0.11 µg/L [examples from JRC 
RM catalog 39, CRMs IRMM-449 and ERM-DA481/IFCC, respectively]). A 
special category are RMs used for presence/absence testing, where the property is 
typically expressed as probability of detection (e.g., Staphylococcus aureus 
enterotoxin A (SEA) in cheese, CRM IRMM-359) 40. 
A certified reference material (CRM) is an RM characterized by a 
metrologically valid procedure for one or more specified properties, accompanied 
by an RM certificate that provides the value of the specified property (the certified 
value), its associated uncertainty, and a statement of metrological traceability 38. 
The associated uncertainty is expressed as so-called expanded uncertainty, which 
has the meaning of a confidence interval in which the true value lies with a certain 
probability, typically 95%. The qualification requirements for CRM producers are 
laid down in ISO 17034 ("General requirements for the competence of reference 
material producers")41, a standard which recently has been published after its 
conversion from the former ISO Guide 3442. The Reference Materials Unit within 
JRC Geel (formerly Institute for Reference Materials and Measurements, IRMM) 
obtained accreditation to ISO Guide 34 in 2004, and is meanwhile accredited 
according to ISO 17034. Whenever possible, RM production (processing and 
certification) projects are carried out under this accreditation. In addition, all 
finalized projects undergo review by subject-specific external expert panels 
before respective materials are released for sales. Metrological traceability is a 
key concept of metrology and is strongly connected with uncertainty. 
Metrological traceability is defined as "property of a measurement result whereby 
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the result can be related to a reference through a documented unbroken chain of 
calibrations, each contributing to the measurement uncertainty" 43-44. The practical 
meaning is that if a valid metrological traceability chain is established, the 
measurement result in a laboratory using its in-house routine method and 
analyzing a routine sample can be linked to a metrological reference as anchor 
point, which can be the practical realization of an SI unit (e.g., sample mass is 
5.02 kg), a measurement procedure (e.g., amyloid β1-42 peptide as obtained by 
solid phase extraction and subsequent quantification by liquid chromatography 
with mass spectrometry detection, according to the reference methods 45-46), or an 
artifact (e.g., 1 international unit (IU) is equivalent to 0.0347 mg of human insulin 
47). Metrological traceability is essential to make results comparable over time and 
space, with profound consequences, e.g., in pharmaceutical products and in 
international trade (import and export of goods). Metrological traceability is 
undoubtedly important for measurement results, but equally important for 
certified values of a CRM. Establishment of metrological traceability is 
accomplished by using existing CRMs of qualified National Metrology Institutes 
(NMIs) or other institutions of equivalently demonstrated competence. In this 
specific case, no such CRMs are available, which rules out this possibility. 
Another means, however, is a demonstration of the RM producer's competence, 
e.g., through participation in key comparisons under the umbrella of the  CIPM-
MRA (Mutual Recognition Arrangement under the Comité International des 
Poids et Mesures/International Committee for Weights and Measures). JRC Geel 
(formerly IRMM) has participated in various studies organized in dedicated 
CCQM (Consultative Committee for Amount of Substance: Metrology in 
Chemisty and Biology) working groups (e.g., Bioanalysis Working Group, 
recently further split down into Protein Analysis48, DNA Analysis, and Cell 
Analysis Working Groups; Organic Analysis Working Group, Inorganic Analysis 
Working Group). The intercomparisons among NMIs serve as benchmark and aim 
at demonstrating the degree of equivalence of results obtained by the participants. 
 
Another important metrological concept shall be briefly mentioned: 
commutability of a CRM. It shall be understood as the degree of equivalence in 
the analytical behavior of real samples and a CRM with respect to various 
measurement procedures (methods). The term commutability originated from the 
clinical chemistry field 49. It describes the ability of an RM to have inter-assay 
properties comparable to the properties demonstrated by authentic clinical 
samples when measured by more than one analytical method 50. Preparation of the 
CRM (formulation procedures as lyophilization, additives for preservation) can 
potentially lead to non-commutability of the material, for instance due to 
alteration of the analyte and/or changes in the matrix which impairs extraction 
efficiency of the analyte. 
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Investigation of suitable commutability is especially important for matrix CRMs. 
Again, various examples can be listed from the clinical RM sector where 
dedicated commutability studies aim to demonstrate that the RM investigated 
behaves in the same or comparable way to patient samples 51.  
 
The certificate of a CRM describes the material, indicates the property value 
(certified value), its corresponding uncertainty, in case of method-dependent 
measurands the method(s) that was (were) used to obtain the data contributing to 
establish the certified value and its uncertainty, the reference to which the certified 
value is traceable, and the name and function of the RM producer's approving 
officer 52. Moreover, other information typically present on CRM certificates 
include safety information, instructions for storage, how and what to use the 
material for, reconstitution protocol, if applicable, and a legal disclaimer.  
 
The typical uses of CRMs comprise the following applications:  
 Calibration of a method. Typically, calibrants are pure substances or 
solutions of a pure substance (a small molecule, but also biomolecules 
such as a protein). There are some exceptions, especially in the clinical 
field, where matrix CRMs – a calibrant spiked in defined amount into a 
given matrix – are used for calibration: If an isolated pure protein would 
behave differently in a measurement process compared to a sample 
where that protein is in its natural matrix (e.g., human serum), matrix 
CRMs are recommended for method calibration. 
 Validation of methods. For assessing the trueness of a method, a matrix 
CRM is indispensable since all extraction steps are included in the 
analytical workflow. 
 Method performance verification. In this context, the CRM is used as 
QC sample. The aim is to demonstrate that when applying the method, 
the certified value is found, thus the method performs correctly.  
It is important to note that for each CRM it has to be defined case-by-case for 
which purpose and application it can be used. For instance, a calibrant solution 
can be used in method validation studies, but not for the parameter trueness 
(matrix is absent). As mentioned earlier, a matrix CRM on the other hand is 
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Development of RMs and CRMs 
The development of RMs and especially CRMs is a complex process. 





Figure 1. General procedure for CRM production applied at JRC Geel. 53 
 
Material selection can sometimes be difficult, especially for some matrix RMs 
(e.g., decision on exact matrix or accessibility of suitable raw materials). Often 
orienting feasibility studies are required, for instance to investigate how 
processing of a suitable RM can be performed. Processing usually is a multi-step 
process, i.e. to convert a raw material such as plant seeds containing a biological 
toxin into an RM preparation, here a purified toxin isoform. Processing typically 
contains several steps. It can comprise but is not limited to extraction, purification 
by means of preparative chromatography (different modes), formulation, 
aliquoting into containers, and lyophilization. Once the so-called candidate RM 
batch is produced, it is aliquoted into the final storage containers (e.g., plastic 
vials), ensuring that no filling trends occur over the large number of containers 
filled. 
 
Homogeneity is a key requirement for any RM aliquoted into units. To 
demonstrate suitable homogeneity, a study is carried out to verify equivalence 
between the units produced and to quantify the between-unit variation 54. Stability 
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testing is necessary to establish the conditions for storage (long-term stability) as 
well as the conditions for dispatch of the materials to the customers (short-term 
stability). Again, dedicated studies are executed to demonstrate at which 
temperatures the RM (CRM) can be safely stored (e.g., -80 °C) and how 
shipments have to be executed (e.g., dry ice shipment to customer). Whenever 
possible, so-called isochronous stability studies are the primary choice, as 
measurements will be carried out in a large series, thereby adhering to 
repeatability conditions and thus minimizing the variability that stems from 
measurements 55. 
 
One central aspect as concerns measurements within an RM (CRM) project is the 
availability and accessibility of high-performing methods, i.e. methods to be used 
for homogeneity and stability measurements (key parameters precision and 
intermediate precision) and essentially for characterization (key parameters 
trueness, precision and intermediate precision). Characterization of RMs is 
defined as determination of the property values or attributes of an RM, as part of 
the production process. These property values (e.g., protein mass concentration of 
toxin X as established by method Y is 1.52 mg/mL) once established are then 
called certified values when the RM project is completed and certificates have 
been established (value, assigned to a property of an RM that is accompanied by 
an uncertainty statement and a statement of metrological traceability, identified 
as such in the RM certificate 38).  
 
Strictly speaking, validation of methods – especially the parameter trueness –  
require CRMs, and, vice versa, the production of CRMs (establishment of 
certified values for a given property) require validated methods, whereby trueness 
and precision ("accuracy") is key. This vicious circle or chicken-egg dilemma can 
only be overcome by a step-wise approach. To this end, it is crucial to understand 
the methods (measurement processes) to the best possible extent. This comprises 
but is not limited to comprehensive validation (e.g., assessment of specificity, 
extraction recoveries and matrix effects), use of existing suitable CRMs whenever 
possible, and regular participation in PT studies to demonstrate the competent 
application of a method in a laboratory. RMs from JRC Geel come with 
comprehensive documentation: the RM certificate and a certification report, 
which outlines the background, production of the material, homogeneity, stability 
and characterization studies and results, value assignment, uncertainty 
calculation, metrological traceability statement, list of references, and annexes in 





Zeleny et al_revised manuscript_19-08-2019  10
Challenges in the Development of CRMs for Protein Toxins 
As mentioned above, the current EU-project EuroBioTox addresses the 
production and characterization of CRMs for different plant and bacterial protein 
toxins, among them ricin, BoNT and SEB. Specifically for those high molecular 
weight toxins, there are a number of practical challenges to deal with. 
 
1) The purification or production strategy has to be decided on – shall the 
CRMs be produced by purification of toxins from their natural sources or shall 
they be produced by recombinant technologies? Actually, the answer has to be 
given on a case-by-case basis and is closely linked to the molecular characteristics 
of the toxin CRM to be produced.  
 
As an example, ricin is a plant toxin with a complex and variable glycosylation 
pattern containing four glycosylation sites, two on the A and B chains each 8, 56. 
Importantly, the type and level of glycosylation affects the functional activity of 
ricin 20, 57-58: of differently glycosylated ricin isoforms tested, the highest 
glycosylated form, containing more hybrid/complex-type glycans, was most toxic 
in different biological assays tested. Conversely, chemically deglycosylated ricin 
A turned out to be approximately 1000-fold less toxic than glycosylated ricin A 
59. N-glycosylation was shown to promote the toxicity of the ricin A chain by 
promoting its transport out of the endoplasmic reticulum 60. In light of the 
available information on ricin’s functional activity, the authentic glycosylation 
pattern seems to be crucial for its enzymatic activity. Therefore, production from 
natural sources is – for the glycoprotein ricin – a superior approach compared to 
recombinant expression, which most likely would not result in correctly 
glycosylated toxin. Also, considering the cellular toxicity of full-length ricin, 
recombinant production would be difficult to pursue in eukaryotic expression 
systems (which in principle are able to deliver glycosylation). As an alternative 
production strategy and to circumvent ricin’s cytotoxicity, advanced cell-free 
expression systems could be used which are able to add post-translational 
modifications; however, the authenticity of the glycosylation pattern compared to 
the natural plant-derived toxin would have to be proven. 
 
The method of choice for non-glycosylated bacterial toxins such as SE and BoNT 
is the recombinant production, e.g., in E. coli, which ensures reliable expression, 
high yields and purity following established protocols. Especially the anaerobic 
cultivation of Clostridium botulinum is empiric and error prone. In addition, 
BoNT is encoded together with up to five neurotoxin-associated proteins (NAPs) 
such as the non-toxic non-hemagglutin of 140 kDa and three hemagglutinins 
which form large toxin complexes up to 760 kDa. Isolating the 150 kDa BoNT 
from these toxin complexes is challenging and requires sophisticated procedures. 
The drug substances of all currently approved BoNT-based pharmaceuticals are 
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isolated as toxin complex from C. botulinum culture supernatant, but only two 
drug products (inco- and daxibotulinumtoxin A) comprise just the pure 150 kDa 
BoNT/A illustrating the challenge to separate BoNT from the NAPs. Recently, 
the first recombinantly produced BoNT drug product (rBoNT-E) was successfully 
evaluated in a clinical phase I trial (EudraCT 2016-002609-20) and further 
recombinantly produced BoNTs are in development as pharmaceuticals. In case 
of BoNT and SE with their >40 and >26 toxin variants, respectively, it is 
extremely valuable being able to use codon-optimized synthetic genes. This 
approach allows the expression of any toxin whose sequence is known or 
deposited in a public database without the need to obtain the natural producing 
strain or its genomic DNA. One important prerequisite, however, is that it can be 
demonstrated in a pre-study that native and recombinant protein behave the same 
way or at least as similar as possible in different methods. For instance, if the toxin 
was equipped with an affinity peptide tag to increase the isolation efficiency, the 
tag removal after purification is important so that the interaction in an 
immunochemical assay (e.g., ELISA) or in a functional assay is not impaired. In 
contrast to SEs, BoNTs are classical AB-toxins and require proteolytic activation 
into a 50 kDa light chain (LC) and a 100 kDa heavy chain (HC) which remain 
covalently linked by a disulfide bridge for biological activity. Since recombinant 
expression of BoNTs in E. coli yields a single polypeptide chain which is 
biologically inactive, subsequent specific and quantitative hydrolysis (>95% di-
chain BoNT) at a defined loop region between LC and HC is essential to obtain 
biological activity. This process is best controlled in vitro with specific proteases 
and, if necessary, with an engineered loop sequence. Of course, the used protease, 
any peptides cut out from the loop as well as affinity tags cleaved off the BoNT 
need to be quantitatively removed at a rather late stage of the purification process 
to ensure high purity of the RM. Some BoNT variants like all BoNT/E subtypes 
are released by group II non-proteolytic C. botulinum and hence always occur as 
single polypeptide chain with low biological activity until being hydrolyzed in the 
patients’ gastrointestinal tract. In contrast, a recombinantly produced BoNT/E 
including a proteolytic activation step already yields the biological highly active 
toxin which is suitable as RM for sensitive detection methods. Whereas the 
biological consequences of the disulfide bond formation in e.g. SEB is yet 
unknown, BoNTs absolutely depend on the intact disulfide bond connecting LC 
and HC to exert their neurotoxicity. Due to the aerobic conditions during 
recombinant expression and isolation of the BoNT its formation has been proven 
for all established BoNT serotypes 61. Altogether, the ‘recombinant way’ is highly 
suitable for the production of SE and BoNT RM. 
 
2) A second important decision in the planning phase of a toxin CRM project is 
the decision on which molecular toxin variant to use. Is it more appropriate to 
use one isolated toxin variant – and if yes, which one, or would a defined mixture 
of naturally occurring variants better reflect the analytical task? The large batch 
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size of CRMs has to be taken into account: can the selected toxin variant be 
produced in sufficient amount and purity? Generally, a high purity of the analyte 
(≥ 95%) is desirable in a CRM production process. Lower purity preparations are 
acceptable if the uncertainty of the certified value is adjusted accordingly with 
properly estimated contributions from respective impurities. Residual  impurities 
have to be identified and quantified individually whenever possible. This includes 
not only protein/peptide impurities, but also impurities of other nature, e.g. 
inorganic impurities62 
   
Considering the occurrence of plant toxins in multi-gene families, the 
differentiation of the analyte toxin in the CRM from co-purified residual 
impurities can be challenging when purifying from natural sources 20. As an 
example, ricin occurs in two major isolectins, ricin D and ricin E, which are 
present in most R. communis cultivars and are 97% identical on the protein level 
63-65. Ricin is composed of a cell-binding B subunit and an enzymatically active A 
subunit, both linked by a single disulfide bond forming a 63 kDa protein 66. 
Additionally, the plant expresses a highly related molecule called Ricinus 
communis agglutinin (RCA120) which is a tetrameric protein of two ricin A-like 
and two ricin B-like subunits. The identity on the protein level between the A and 
B chains of ricin D to those of the related RCA120 is 94% and 84%, and 94% and 
89% for ricin E, respectively 67. Starting from a cultivar expressing all three 
molecules, the presence of ricin E concomitant to RCA120 cannot be clearly 
differentiated and quantified from ricin D by LC-MS/MS on the protein level. 
Therefore, a more straight-forward strategy for the production of a ricin CRM is 
to start with the cultivar R. communis zansibarienis which has been shown to 
produce ricin D only 68. Here, ricin D and RCA120 can be separated in sufficient 
amount and purity by preparative chromatography.  
 
Due to gene synthesis, recombinant expression of a toxin offers maximal freedom 
with respect to selection of the variant. One criterium would be the 
epidemiological occurrence of the variant, but also biosecurity aspects need to be 
considered for selecting the toxin variant. As an example, BoNTs pathogenic to 
humans occur in more than 40 different variants called subtypes, which vary up 
to 36% on the amino acid level 69. Subsequently, molecule characteristics like 
high specific toxicity to humans (to stress the sensitivity of methods to be 
validated), high water solubility, sufficient stability with respect to protein mass 
concentration as well as specific toxicity (in commonly usable formulations) and 
acceptable yield by the production process guide the selection process.  
 
3) A third critical point to consider is the molecular integrity of the toxin CRM 
at the end of the production process. It has to be made sure that the production 
process (including purification/expression, filling, storage) does not compromise 
the identity and function of the analyte. To this end, the comparability of the toxin 
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CRM to its natural, authentic analog should be demonstrated by a panel of 
different methods (see below). Generally, the formulation of the toxin CRM, e.g., 
the buffer composition in case of a CRM solution, has to be carefully selected so 
that a comprehensive characterization of the CRM is technically feasible. It has 
to be considered that additives might stabilize the toxin CRM, but might interfere 
with certain measurement procedures (e.g., addition of protein stabilizers or salt 
might interfere with MS-based methods, detergents impair analysis in cell-based 
methods); therefore, the use of additives should be minimized. 
 
4) Finally, the whole production chain for toxin CRMs requires appropriate safety 
and security measures in place including a concept for safe storage and 
distribution. This goes beyond conventional safety and security measures since 
the large-scale production of toxin CRMs imposes additional challenges, namely 
upscaling issues. Generally, working with biological toxins requires physical 
security measures such as working in highly secured laboratories equipped with 
biological safety cabinets for delicate sample handling and having 
decontamination agents available in case of spill. In addition to these biosafety 
measures, biosecurity measures have to be implemented, such as facility security 
plans (e.g., data and IT security, emergency response plans, procedures for 
receipt, transfer and shipment of select agents), personnel access control, 
personnel registration and security vetting, operational control and regular staff 
training. Additionally, risk assessments for all procedures need to be documented 
prior to the practical work. This includes information on adequate personal 
protective equipment, decontamination procedures and operational safety 
measures. There are useful references, which describe safety and health 
considerations for conducting work with biological toxins 70-72. 
 
Characterization of Toxin CRMs 
 
As mentioned above, availability of and accessibility to high-performance 
methods are key for the characterization of toxin CRMs. Apart from 
measurements for homogeneity, stability and characterization, this also accounts 
for the purity and identity assessment of the produced toxins. A variety of methods 
has to be applied to demonstrate identity and suitable purity of the preparations 
(Figure 2). These comprise but are not limited to liquid chromatography – 
(tandem) mass spectrometry (peptide fingerprinting and protein sequencing for 
identification; LC-MS of intact protein for exact mass determination), MALDI-
TOF MS and other MS techniques to detect protein or peptide impurities, 
immunochemical methods such as ELISA and Western Blot as well as SDS-
PAGE and/or capillary gel electrophoresis for a purity profile. In addition, for 
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glycosylated protein toxins a set of methods is required dedicated to 
comprehensive glycosylation analysis (identification of glycans and glycoforms). 
Typically, LC-MS methods are applied to identify the glycans, their structures 
and microheterogeneity, and to identify which N-glycosylation sites are occupied. 
 
The mass concentration of the protein toxin in solution will best be quantified 
using protein impurity corrected amino acid analysis. It involves quantification of 
constituent amino acids following complete hydrolysis of the material and 
correction for amino acids originating from inherent structurally-related protein 
impurities. Individual amino acids are separated by liquid chromatography or gas 
chromatography (GC) and quantified, typically using isotope dilution mass 
spectrometry 62, 73-75. The protein mass concentration is calculated taking into 
account the amino acid sequence of the protein. This approach requires a highly 
purified protein preparation; therefore the above-mentioned analyses are 
performed first to confirm a high level of purity. The speed and completeness of 
acidic hydrolysis of the protein to amino acids, both indispensable requirements 




Figure 2. Characterization of toxin CRM requires a comprehensive and 
complementary panel of different methods. 
 
Finally, different functional assays are required to assess the toxicity and/or 
biological activity of the toxin preparation. This is challenging since it is not 
obvious to link the precise protein amount to its biological activity – the outcome 
of activity determination heavily depends on the method used. For example, for 
ricin the measurement of cytotoxicity in vitro displays the activity of the A and 
the B chain (cell binding plus enzymatic activity), while adenine release assay 
indicates enzymatic activity only 19-20. Likewise, for BoNTs it has been shown 
that the potency of different serotypes relative to each other is different by its 
quantitative factor when either in vivo (mouse bioassay) or ex vivo (mouse phrenic 
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nerve assay) methods are used 61. This can be explained by the fact that the mouse 
bioassay describes the pharmacodynamics plus the pharmacokinetics of BoNT 
including absorption, distribution, metabolism and elimination from circulation 
of the individual BoNTs, while factors such as distribution, metabolism or 
elimination are not displayed in the mouse phrenic nerve assay. This discrepancy 
was extended by comparing the biological activity of the six native BoNT/A-F in 
in vitro cell-based assays (neurotransmitter release vs. substrate [SNARE protein] 
cleavage), ex vivo MPN assay and in vivo sublethal digital abduction score assay 
77. With respect to value assignment in a toxin CRM project it is therefore 
imperative to describe the functional method used in great detail so that it can be 
reproduced by the CRM customer. 
 
Special Consideration of the Use of Toxin CRMs in Mass 
Spectrometry 
 
From the different methods in use for detection of biological toxins, MS-based 
methods clearly display the highest specificity and allow for unambiguous 
identification of the analyte 23-24, 78-79. Here, the availability of toxin CRMs is 
highly useful to develop the technology forward in terms of toxin identification, 
quantification and sample preparation.  
 
Toxin identification is typically based on peptide mass fingerprinting of digested 
protein matched against the theoretical peptide masses derived in silico, nowadays 
often realized in MS/MS-based approaches. The availability of pure CRMs makes 
it possible to generate high-quality peptide spectral libraries for forensic 
identification of closely related protein toxins. Based on an in silico digest, it is 
important to determine which of the theoretically possible prototypic peptides can 
be measured experimentally with sufficient intensity and/or sensitivity depending 
on the instrumentation used. This information is a prerequisite to select diagnostic 
peptides for an overall workflow to be applied in the course of a forensic 
investigation 80-82. Here, a regular verification of the selected diagnostic peptides 
against peptides derived from newly identified proteins is recommended to 
maintain specificity and hence unambiguous identification of the toxin 80. 
 
Many state-of-the-art MS-based approaches are quite sensitive (low limits of 
detection and quantification). This can trigger matrix effect issues if a highly pure 
toxin is present at very low mass concentration in a buffer/matrix (unfavorable 
mass ratio of matrix to analyte). Highly pure toxin CRMs are important for the 
improvement of analytical procedures with respect to developing sample 
preparation methods, assessing recovery and in documenting the overall 
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efficiency and reproducibility of the workflow. Toxin CRMs will furthermore 
support the determination of the enzymatic digestion efficiency in order to obtain 
high sequence coverage. 
 
Conclusions and Outlook 
 
CRMs, thoroughly validated methods and PT studies are cornerstones of applied 
quality assurance. They are important QC tools for laboratories to validate and 
safeguard analytical methods. One of the main deliverables in the EuroBioTox 
project is the development and production of CRMs for plant and bacterial protein 
toxins. As in other fields, ideally pure substances for calibration (calibrants, either 
solutions or solid materials) as well as matrix RMs containing the analyte in a 
defined amount in a complex matrix representing a typical sample material (e.g., 
toxin spiked into serum, food matrix, water) for method validation would be 
available. Producers of high-quality CRMs face several challenges regarding the 
purification or production process and the choice of the toxin variant to be 
produced. Safeguarding the molecular integrityof the analyte during the 
production process as well as high purity and biological activity of the CRM are 
key elements of the process. Above all, appropriate safety and security measures 
have to be in place to deal with the task. 
 
The provision of such materials shall improve the preparedness and competence 
of laboratories to reliably analyse samples for biological toxins. Application fields 
are not limited to the food safety and public health sectors, but are equally 
important in security, military, and verification sectors. Overall, harmonized and 
standardized laboratory detection will enhance preparedness and response 
planning and will help to maintain a high level of vigilance, thus increasing 
resilience of the civil society in the capacity to prepare and respond to an incident 
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BoNT  Botulinum neurotoxin 
CCQM Consultative Committee for Amount of Substance: Metrology 
in Chemisty and Biology 
CRM  Certified reference material 
ELISA  Enzyme-linked immunosorbent assay 
EQuATox EU-project, acronym: Establishment of Quality Assurances for 
the Detection of Biological Toxins of Potential Bioterrorism 
Risk 
EU  European Union 
EuroBioTox EU-project, acronym: European Programme for the 
Establishment of Validated Procedures for the Detection and 
Identification of Biological Toxins 
GC Gas chromatography 
HC  Heavy chain of BoNT 
LC  Light chain of BoNT 
LC-ESI MS  Liquid chromatography-electrospray ionization-tandem mass 
spectrometry 
MALDI-TOF Matrix-Assisted Laser Desorption Ionization—Time of Flight 
MHC  Major histocompatibility complex 
MS  Mass spectrometry 
NAP  Neurotoxin-associated proteins 
NMIs  National Metrology Institutes 
PT  Proficiency test 
QC  quality-control 
RM  Reference material 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SE  Staphylococcal enterotoxin 
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